Novo Nordisk | NVO - Ebitda

Aktienkurs
38.56
Täglich Wechseln
0.52 1.37%
Monatlich
-21.83%
Jährlich
-50.06%
Q1 Prognose
35.99




Ebitda Veränderung Datum
ANI Pharmaceuticals USD 65.36M 5.76M 2025-12
Aurora Cannabis CAD 15.37M 26.8M 2025-09
Bausch Health Companies USD 986M 74M 2025-09
Bristol-Myers Squibb USD 4.24B 967M 2025-09
Canopy Growth CAD 16.62M 38.45M 2025-09
Corcept Therapeutics USD 4.2M 6.5M 2025-12
Drreddys Laboratories INR 21.59B 1.49B 2025-12
Eli Lilly USD 7.88B 378.1M 2025-09
GlaxoSmithKline GBP 3.36B 179M 2025-09
Merck USD 8.39B 1.97B 2025-09
Nektar Therapeutics USD -31.81M 70K 2023-09
Novartis USD 5.88B 290M 2025-09
Novo Nordisk DKK 37.3B 5.86B 2025-12
Novo Nordisk DKK 31.44B 6.84B 2025-09
Pacira USD 38.71M 10.65M 2025-12
Perrigo USD 258.8M 37.3M 2025-09
Phibro Animal Health USD 68.1M 6.2M 2025-12
Prestige Brands USD 90.82M 3.99M 2025-12
Sanofi EUR 4.84B 2.95B 2025-09
Supernus Pharmaceuticals USD 48.5M 6.6M 2025-12
Zoetis USD 1.04B 87M 2025-09